Novartis Vanrafia Phase III data support slowing of kidney function decline in patients with IgA nephropathy
Basel, February 13, 2026 – Novartis today announced final results from the…
Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed…
Press Release Biocartis NV: Biocartis Announces IVDR Class C CDx Certification of the Idylla EGFR Mutation Test
PRESS RELEASE 02/06/2025, 10:00 CEST Biocartis Announces IVDR Class C CDx Certification…